生物制剂和小分子药物在慢性荨麻疹治疗中的作用进展

Progress of Biologics and Small Molecule Drugs in the Therapy of Chronic Urticaria

二代抗组胺药目前仍是慢性荨麻疹的一线治疗药物,但对于慢性难治性荨麻疹患者的疗效则不尽如人意。随着临床研究的深入开展,越来越多的生物制剂和小分子药物,如奥马珠单抗、利戈丽珠单抗、白三烯受体拮抗剂、三环类抗抑郁药、免疫抑制剂等,被证明联合抗组胺药治疗对于荨麻疹具有良好的治疗效果。随着技术的不断发展和研究的陆续开展,此类药物有望成为慢性荨麻疹治疗的新方向,将具有更广阔的应用前景。

The first-line therapy for chronic urticaria is the second generation histamine H1 receptor antagonist.However,some patients with chronic refractory urticaria using regular doses of histamine H1 receptor antagonist have no obvious effect.According to clinical observation,the curative effect of combination therapy of chronic urticaria is superior to using histamine H1 receptor antagonist alone.The commonly used biological agents and small molecule drugs include omalizumab,ligelizumab,leukotriene receptor antagonist,tricyclic antidepressants,immunosuppressants,etc.It will have broad application prospect in the treatment of chronic urticaria with the development.